Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B
Authors: Jian Wang, Weimao Ding, Jiacheng Liu, Yong Liu, Xiaomin Yan, Juan Xia, Weihua Wu, Bei Jia, Yuxin Chen, Dongmei Gao, Shuqin Hong, Xiaohong Wang, Li Wang, Xin Tong, Shengxia Yin, Zhaoping Zhang, Jie Li, Rui Huang, Chao Wu
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Coexistence of hepatitis B surface antigen (HBsAg) and antibody against HBsAg (anti-HBs) constitutes an atypical serological profile in chronic hepatitis B virus infection, and the association between coexistent HBsAg and anti-HBs with severe liver fibrosis and cirrhosis in patients with chronic hepatitis B (CHB) remains unclear. <h3>Objective</h3> To investigate the association of coexistent HBsAg and anti-HBs with severe liver fibrosis and cirrhosis in patients with CHB. <h3>Design, Setting, and Participants</h3> Consecutive treatment-naive patients with CHB from 2 medical institutions in China were enrolled between January 10, 2015, and March 31, 2021. Severe liver fibrosis and cirrhosis were identified using the aspartate transaminase (AST) to platelet ratio index (APRI), the fibrosis index based on 4 factors (FIB-4; factors comprise age, AST level, alanine aminotransferase [ALT] level, and platelet count), transient elastography, or ultrasonography. Data were analyzed from August 1, 2021, to April 15, 2022. <h3>Main Outcomes and Measures</h3> The primary outcomes were rates of severe liver fibrosis and cirrhosis among patients with vs patients without coexistant HBsAg and anti-HBs. Severe liver fibrosis was defined as an APRI score of 1.5 or higher, a FIB-4 score of 3.25 or higher, or a liver stiffness measurement of 8 kPa or higher; cirrhosis was defined as an APRI score of 2.0 or higher, a FIB-4 score of 6.5 or higher, a liver stiffness measurement of 11 kPa or higher, or ultrasonographic findings suggestive of cirrhosis. <h3>Results</h3> Of 6534 enrolled patients, 4033 patients (61.7%) were male, and the median (IQR) age was 41.0 (33.0-52.0) years. A total of 277 patients (4.2%) had coexistent HBsAg and anti-HBs. Patients with vs without anti-HBs were older (median [IQR], 46.0 [33.0-55.5] years vs 41.0 [33.0-52.0] years) and had a higher proportion of hepatitis B e antigen (HBeAg) positivity (123 of 277 patients [44.4%] vs 2115 of 6257 patients [33.8%];<i>P</i> &lt; .001), higher ALT levels (median [IQR], 45.1 [24.6-119.0] U/L vs 36.7 [22.0-77.0] U/L;<i>P</i> = .001) and AST levels (median [IQR], 35.0 [23.5-68.4] U/L vs 28.3 [21.6-51.0] U/L;<i>P</i> &lt; .001), and lower platelet counts (median [IQR], 173.0 × 10<sup>3</sup>/μL [129.0-212.5 × 10<sup>3</sup>/μL] vs 185.0 × 10<sup>3</sup>/μL [141.0-224.0 × 10<sup>3</sup>/μL];<i>P</i> = .004), albumin levels (median [IQR], 4.37 [4.11-4.56] g/dL vs 4.43 [4.17-4.61] g/dL;<i>P</i> = .02), and HBsAg levels (median [IQR], 2.8 log<sub>10</sub>[1.6-3.4 log<sub>10</sub>] IU/mL vs 3.3 log<sub>10</sub>[2.6-3.9 log<sub>10</sub>] IU/mL;<i>P</i> &lt; .001). Compared with patients without anti-HBs, those with anti-HBs had higher APRI scores (median [IQR], 0.5 [0.3-1.4] vs 0.4 [0.3-0.9];<i>P</i> &lt; .001), FIB-4 scores (median [IQR], 1.4 [0.9-2.6] vs 1.1 [0.7-2.1];<i>P</i> &lt; .001), and liver stiffness values (median [IQR], 7.5 [6.2-9.8] kPa vs 6.3 [5.2-8.1] kPa;<i>P</i> = .003). Patients with anti-HBs also had higher proportions of severe liver fibrosis (102 of 277 patients [36.8%] vs 1397 of 6207 patients [22.5%];<i>P</i> &lt; .001) and cirrhosis (87 of 277 patients [31.4%] vs 1194 of 6213 patients [19.2%];<i>P</i> &lt; .001) compared with patients without anti-HBs. The coexistence of HBsAg and anti-HBs was independently associated with severe liver fibrosis (odds ratio [OR], 2.29; 95% CI, 1.56-3.38;<i>P</i> &lt; .001) and cirrhosis (OR, 1.73; 95% CI, 1.12-2.68;<i>P</i> = .01) in the multivariate analysis. However, the association of coexistent HBsAg and anti-HBs with cirrhosis was only observed in patients with HBeAg negativity (OR, 1.66; 95% CI, 1.05-2.62;<i>P</i> = .03) and not in patients with HBeAg positivity (OR, 1.45; 95% CI, 0.87-2.43;<i>P</i> = .16). <h3>Conclusions and Relevance</h3> In this cross-sectional study, the coexistence of HBsAg and anti-HBs was unusual in hepatitis B virus infection and was associated with more advanced liver diseases, such as severe liver fibrosis and cirrhosis, especially among patients with HBeAg negativity. These results suggest that close monitoring for liver fibrosis and cirrhosis is warranted in patients with CHB who have this serological profile.